Tracker › Companies › Caribou Biosciences, Inc.
2 No sign of it. We found no public evidence tying Caribou Biosciences, Inc.'s cuts to AI.
Every tracked 2026 layoff at Caribou Biosciences, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 2/100 (Minimal) · 80% interval 2–3 · evidence grade D · CA · Pharma / Chemicals
Stated reason: On October 2, 2026, the Board of Directors (the “Board”) of Caribou Biosciences, Inc. (the “Company”) approved a restructuring of the Company’s operations (the “Restructuring”) as the Company conducts a process to explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials and further development activities for the Company’s allogeneic CAR-T cell therapy prog…
Why 2: Plant, store or site closure · Drivers: contrary evidence −0.9, industry AI exposure +0.5
Evidence: SEC filing, state WARN notice. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.608, industry exposure 0.712, AI investment 0.0, contrary evidence 0.55 · named roles: Computer and Information Systems Managers, General and Operations Managers, Nursing Assistants, Registered Nurses
Headcount basis: WARN (sum of state notices; company-wide total not disclosed) · WARN: 87 workers at 1 site notice(s)
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 1,864 workers
Health Care & Pharma · 589 workers
Health Care & Pharma · 303 workers
Health Care & Pharma
Health Care & Pharma
Health Care & Pharma
